|
BCDA | Biocardia, Inc. |
|
|
BCDA | Biocardia, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.05 |
| Leverage | 56.07% |
| Market Cap | $ 51.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -7.7m |
| Margin | -6608.26% |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. The company is headquartered in San Carlos, California.